Panel backs Celgene's blood-disorder drug

09/15/2005 | Wall Street Journal, The

The panel of experts voted 10-5 to back the Celgene drug Revlimid for patients with myelodysplastic syndromes, based on Phase II studies of patients with MDS who have a certain genetic abnormality. The majority of those voting against approval said they wanted to wait for data from a Phase III study now beginning to enroll patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA